Combined etiology of anaphylactic cardiogenic shock: Amiodarone, epinephrine, cardioverter defibrillator, left ventricular assist devices and the Kounis syndrome

Nicholas G. Kounis, George D. Soufras, Periklis Davlouros, Grigorios Tsigkas, George Hahalis
Department of Cardiology, University of Patras Medical School, Patras, Rio, Achaia, Greece

ABSTRACT
Anaphylactic shock is a life-threatening condition which needs detailed and medidious clinical assessment and thoughtful treatment. Several causes can join forces in order to degranulate mast cells. Amiodarone which is an iodine-containing highly lipophilic benzofuran can induce allergic reactions and anaphylactic shock in sensitized patients. Epinephrine is a life saving drug, but in sulfite allergic patients it should be given with caution due its metabisulfite preservative. Metals covering cardiac defibrillators and pacemakers can act as antigens attached to serum proteins and induce allergic reactions. In anaphylactic shock, myocardial involvement due to vasospasm-induced coronary blood flow reduction manifesting as Kounis syndrome should be always considered. Clinically, combined treatment targeting the primary cause of anaphylaxis together with protection of cardiac tissue seems to be of paramount importance.

Key words: Anaphylactic shock; amiodarone; cardioverter defibrillator; epinephrine; Kounis syndrome; left ventricular assist device

INTRODUCTION
Acute myocardial infarction, vasospastic angina and even stent thrombosis can manifest as Kounis hypersensitivity-associated coronary syndrome when follow an allergic, hypersensitivity, anaphylactic or anaphylactoid episode. This syndrome is the result of the action of inflammatory mediators released locally or in the systemic circulation following mast cell degranulation. The released mediators can induce either coronary artery spasm which can progress to acute myocardial infarction or atheromatous plaque erosion or rupture culminating to coronary thrombosis. Vasospastic angina (type I), acute coronary thrombosis (type II) and stent thrombosis (type III) are the three variants of this syndrome that have been described so far. The allergic thrombotic process can also follow activation, by mast cell mediators, of high affinity and low affinity FCγRI, FCγRII, FcεRI and FcεRII receptors situated in the platelet surface. It has been found that mast cells degranulate when 2000 nearby antibodies attached to their surface are bridged by corresponding antigens and make the critical number of 1000 bridges. This can be achieved by antibodies of different specificities and especially in children the combination of several exposures at a given time is related to disease severity. Today, Kounis syndrome is ubiquitous disease affecting patients of any age, from 2 years old to octogenarians, involving numerous and continuously increasing causes, with broadening clinical manifestations. Multiple combined etiologies can join forces and induce anaphylaxis and Kounis syndrome. Amiodarone is used as anti-arrhythmic agent and in combination with arrhythmogenic drugs
can induce anaphylaxis as it has been reported recently in the Annals of Cardiac Anesthesia.\textsuperscript{6,7} In addition, anaphylactic cardiogenic shock following amiodarone administration has occurred in a 15-year-old boy with a history of tuberous sclerosis, and a large nonobstructive cardiac rhabdomyoma in the left ventricle.\textsuperscript{8} The patient had tumour-associated ventricular tachycardia episodes. Despite treatment with inotropes and epinephrine his condition worsened with severely depressed biventricular function necessitating support with left ventricular assist device, the centrifugal Rotaflow (Maquet, Gentige group, Rastatt, Germany). His electrocardiogram showed myocardial ischemia with ST segment elevation in the inferior and lateral leads. He received methylprednisone for a 5-day course for anaphylactic shock had a good recovery and was discharged home with normal systolic function and baseline neurologic status. The patient had cardioverter defibrillator implantation due to episodes of unstable ventricular tachycardia and had been subjected to several amiodarone exposures in the past. The authors of this report wondered whether this was a case of Kounis syndrome or was the result of epinephrine administration. These reports, really, raise important questions especially when amiodarone, epinephrine, cardioverter defibrillator, left ventricular assist devices, anaphylactic cardiogenic shock are combined in anesthetized cardiac patients.

**AMIODARONE-INDUCED ALLERGIC REACTIONS**

Most of the severe systemic adverse reactions of amiodarone are well known and concern skin, lung, thyroid gland, liver peripheral nerves and platelets. This drug is an iodine-containing highly lipophilic benzofuran derivative serving a class II long-acting anti-arrhythmic, capable of blocking both α and β-adrenoceptors. The incidence of amiodarone-induced hypersensitivity reactions in hospitalized patients with a listed allergy to iodine or iodinated contrast agents was found to be <1%.\textsuperscript{9} Severe anaphylactic reactions with cardiogenic shock are rare and only 2 additional cases have been reported\textsuperscript{10} since the publication of Averin et al.\textsuperscript{8} However, iodinated contrast media have induced Kounis syndrome on several occasions.\textsuperscript{11,12} In a recent study\textsuperscript{13} concerning patients with amiodarone-induced thrombocytopenia it was found that this was caused by drug-dependent antibodies specific for platelet glycoproteins GPIa/IIa and/or GPIIb/IIIa. The authors of this study postulated that in vivo, amiodarone may become incorporated into occult lipophilic domains in platelet glycoproteins, producing structural modifications that are immunogenic in some individuals, and that the resulting antibodies can cause platelet destruction in individuals taking this drug.

**EPINEPHRINE ADMINISTRATION IN ANAPHYLAXIS**

Exogenous epinephrine administration is a life saving procedure, but it has been shown to promote platelet activation via specific receptors found on the platelet surface, it also induces platelet aggregation by increasing platelet production of thromboxane B2 and heightening platelet sensitivity to adenosine diphosphate and promotes thrombin induced binding of platelets to fibrinogen.\textsuperscript{14} Epinephrine can aggravate, therefore, myocardial ischemia, prolong QTc interval, and induce coronary vasospasm and arrhythmias. Elderly patients, especially with a history of hypertension and coronary artery disease, are prone to these side effects. In patients who may have received β-blockers in the initial management of the acute coronary syndrome, the usual dose of epinephrine may be ineffective. It may also promote more vasospasm due to unopposed alpha adrenergic effect. Furthermore, commercially available preparations of epinephrine usually contain as a preservative, sodium metabisulfite. This substance is commonly used as an antioxidant in the food and pharmaceutical preparations. There are reports of hypersensitivity, anaphylaxis, and even death from Kounis syndrome from sulfite administration. Anaphylactoid shock has been reported during epidural anesthesia for cesarean section, in which the responsible agent was metabisulfite, as additive agent of epinephrine-containing local anesthetic.\textsuperscript{15} This situation poses a therapeutic dilemma in the sulfite-sensitized patients who suffer from anaphylactic shock. Physicians dealing with anaphylactic shock should be aware of this treacherous association. Although epinephrine is still the primary drug for anaphylaxis, avoidance of medications that contain metabisulfites as preservatives, including epinephrine, is suggested for patients with definite sensitization to sulfites. In this situation, a possible alternative is glucagon which has been used successfully for treatment of anaphylaxis in patients taking β-blockers.\textsuperscript{16} Fortunately, for patients sensitive to sulfites, sulfite-free epinephrine is already commercially available (American Regent Inc., USA).

**CARDIOVERTER DEFIBRILLATORS AND LEFT VENTRICULAR ASSIST DEVICES POTENTIAL ALLERGENIC DEVICES**

Cardioverter defibrillators as well as cardiac pacemakers have generators which are covered with titanium,
conductors wires consisting of an alloy of nickel, cobalt, chromium and molybdenum and pacing electrodes which are made of platinum alloyed with 10–20% iridium.\cite{17} Metal anions eluted from nickel, cobalt, chromium molybdenum and titanium can attach to circulating proteins and act as haptons that behave as allergic sensitizers. Allergy to nickel can occur in up to 24.6% of the population and is the most frequent cause of allergic contact dermatitis.\cite{18} It is also common that patients are sensitized to multiple metal anions. Concurrent sensitization, cross-reactivity or both seem to be possible. It has been shown that sensitization to one metal anion increases the possibility of being sensitized to additional metals. Metals can also “join forces” in order to sensitize individuals. Recently, an increased rate of thrombosis with substantial morbidity and mortality has been reported with the use of HearMate II (Thoratec, Pleasanton, CA, USA) left ventricular assist device.\cite{19} Histology of thrombotic material, deposited near inflow bearing, showed the presence of lymphocytes, plasma cells and eosinophils thus denoting hypersensitivity reaction. Titanium alloy can induce hypersensitivity and immune dysfunctions rendering titanium no longer biologically inert.\cite{20} In the patient reported by Averin et al.\cite{20} a temporary left ventricular assist device, the centrifugal Rotaflow (Marquet), was used which is the only centrifugal pump that comes without a seal or a metal shaft. However, this patient had cardioverter defibrillator implanted with titanium coverage and metallic conductor wires and pacing electrodes able to induce allergic reaction.

**ISCHEMIC MYOCARDIAL DAMAGE AS PRIMARY EVENT IN ANAPHYLACTIC SHOCK**

Experimental studies have shown that during anaphylaxis acute myocardial ischemia, decrease in cardiac output, initial rise in arterial blood pressure and increase in left ventricular end diastolic pressure indicating pump failure are the main findings. The latter, according to the authors, definitely excludes peripheral vasodilatation as a cause of the registered anaphylactic cardiac damage.\cite{21} Clinically there are patients with anaphylactic shock and Kounis syndrome who do not respond to fluids, hydrocortisone, antihistamines and vasopressors but need myocardial infarction protocol treatment.\cite{22} Indeed, in one patient treatment with metaraminol and epinephrine worsened hypotension and annihilated cardiac output.\cite{23} Therefore, myocardial dysfunction due to vasospasm-induced coronary blood flow reduction manifesting as Kounis syndrome should be always considered in cases of anaphylactic shock.

**INCIDENCE OF KOUNIS SYNDROME**

The incidence of anaphylaxis with circulatory symptoms during a 3-year period was estimated in a retrospective study.\cite{24} In this study, 226 individuals suffered 246 episodes of severe life-threatening anaphylaxis with cardiovascular symptoms, with an incidence of 7.9–9.6 per 100,000 inhabitants per year. The case-fatality rate was 0.0001%.\cite{24} As far as Kounis syndrome is concerned, owing to missed and/or undiagnosed cases and a lack of large prospective trials, determining the prevalence and exact incidence is difficult with our current state of knowledge. Although it is considered to be not a rare disease, it is infrequently reported in the literature and recognized in clinical practice.\cite{25} Recent reports have shown that Kounis syndrome has been observed in every race, age group (from 2 to 90 year olds) and geographic location. Increased awareness about its existence and conduction of large prospective trials will help in true estimation of its incidence.\cite{26} In the district of Achaia, Greece with a population of 300,000 inhabitants, and with increased awareness for the existence of Kounis syndrome, 52 cases of this syndrome have been encountered in the last 4 years caused by environmental exposures, drug allergies and stent implantation. The annual incidence of Kounis syndrome in this district was estimated of 4.33 cases/100,000 inhabitants.\cite{27} In a tertiary hospital in Istanbul, Turkey, a total of 3876 patients underwent urgent coronary angiography for suspected acute myocardial infarction during a 3-year period (2006–2009) and eight patients were diagnosed with Kounis syndrome. Thus, the catheterization laboratory prevalence of Kounis syndrome is estimated to be 0.002%\cite{28} Kounis syndrome has mostly been reported in southeastern Europe, especially Greece, Spain, Italy and Turkey. This geographical variation could be attributed to the increased awareness of physicians of the existence of Kounis syndrome, climate and environmental conditions, resulting in pollen cross-reactivities and hymenoptera exposures, overconsumption of medicines, or inadequacy of preventative measures. Gene–environment interactions starting in early life using the epigenetic approach should be also explored too.\cite{1}

**CONCLUSION**

Multiple combined causes including drugs and devices can join forces able to induce anaphylactic shock. Patients simultaneously exposed to various corresponding allergens that can bridge antibodies
with different specificities, are at increased risk. These patients have more symptoms than mono-sensitized individuals. The heart and the coronary arteries, in particular, seem to be primary sites of anaphylaxis. Combined treatment targeting the primary cause of anaphylaxis together with protection of cardiac tissue seems to be of paramount importance.

REFERENCES

1. Kounis NG, Mazarakis A, Tsigkas G, Giannopoulos S, Goudevenos J. Kounis syndrome: A new twist on an old disease. Future Cardiol 2011;7:805-24.

2. Hasegawa S, Tashiro N, Matsubara T, Furukawa S, Ra C. A comparison of FcepsilonRI-mediated RANTES release from human platelets between allergic patients and healthy individuals. Int Arch Allergy Immunol 2001;125 Suppl 1:42-7.

3. Nopp A, Johansson SG, Lundberg M, Oman H. Simultaneous exposure of several allergens has an additive effect on multisensitized basophils. Allergy 2006;61:1366-8.

4. Parent B, Wearden P, Kounis NG, Chrysostomou C. Kounis syndrome or allergic coronary vasospasm in a two-year-old. Congest Heart Dis 2011;6:499-503.

5. Biteker M, Duran NE, Biteker FS, Civan HA, Kaya H, Gökdeniz T, et al. Allergic myocardial infarction in childhood: Kounis syndrome. Eur J Pediatr 2010;169:27-9.

6. Okuyan H, Altin C, Arihan O. Anaphylaxis during intravenous administration of amiodarone. Ann Card Anaesth 2013;16:229-30.

7. Malik I. In response to “Anaphylaxis during intravenous administration of amiodarone”: Is amiodarone the best choice for management of atrial fibrillation? Ann Card Anaesth 2014;17:70-1.

8. Averin K, Lorts A, Connor C. Anaphylactic shock after amiodarone infusion resulting in haemodynamic collapse requiring a temporary ventricular assist device. Cardiol Young 2015;25:164-6.

9. Lakshmanadoss U, Lindsley J, Glick D, Twilley CH, Lewin JJ rd, Marine JE. Incidence of amiodarone hypersensitivity in patients with previous allergy to iodine or iodinated contrast agents. Pharmacotherapy 2012;32:618-22.

10. Muller V, Morell E, Le Marec C, Pasquier P, Rousseau JM. Cardiac arrest at induction of a patient with thyrotoxicosis. Have you thought of anaphylaxis? Ann Fr Anesth Reanim 2010;29:488-90.

11. Kocabay G, Karabay CY, Kounis NG. Myocardial infarction secondary to contrast agent. Contrast effect or type II Kounis syndrome? 2012;3:255.e1-2.

12. Xu M, Wu XS, Jiang TY, He JQ. Kounis syndrome: Allergic acute coronary syndrome. Chin Med J (Engl) 2013;126:2591-2.

13. Sahud MA, Caulfield M, Clarke N, Koch R, Bougie D, Aster R. Acute thrombocytopenia in patients treated with amiodarone is caused by antibodies specific for platelet membrane glycoproteins. Br J Haematol 2013;163:260-7.

14. Soufras GD, Kounis NG. Adrenaline administration for anaphylaxis and the risk of takotsubo and Kounis syndrome. Int J Cardiol 2013;166:281-2.

15. Soulat JM, Bouju P, Oxeda C, Amiot JF. Anaphylactoid shock due to metabisulfites during cesarean section under peridural anesthesia. Cach Anesthesiol 1991;39:257-9.

16. Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005;22:272-3.

17. Honari G, Ellis SG, Wilkoff BL, Aronica MA, Svensson LG, Taylor JS. Hypersensitivity reactions associated with endovascular devices. Contact Dermatitis 2008;59:7-22.

18. Rui F, Bovenzi M, Prodi A, Fortina AB, Romano I, Peserico A, et al. Nickel, cobalt and chromate sensitization and occupation. Contact Dermatitis 2010;62:225-31.

19. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 2014;370:33-40.

20. Muller K, Valentine-Thon E. Hypersensitivity to titanium: Clinical and laboratory evidence. Neuro Endocrinol Lett 2006;27 Suppl 1:31-5.

21. Felix SB, Baumann G, Berdel WE. Systemic anaphylaxis – Separation of cardiac reactions from respiratory and peripheral vascular events. Res Exp Med (Berl) 1990;190:239-52.

22. Mukta V, Chandragiri S, Das AK. Allergic myocardial infarction. N Am J Med Sci 2013;5:157-8.

23. Shah G, Scadding G, Nguyen-Lu N, Wigmore T, Chenzbraun A, Wechalekar K, et al. Peri-operative cardiac arrest with ST elevation secondary to gelofusin anaphylaxis – Kounis syndrome in the anaesthetic room. Int J Cardiol 2013;164:e22-6.

24. Hellbling A, Hurni T, Mueller UR, Pichler WJ. Incidence of anaphylaxis with circulatory symptoms: A study over a 3-year period comprising 940,000 inhabitants of the Swiss Canton Bern. Clin Exp Allergy 2004;34:285-90.

25. Biteker M. Current understanding of Kounis syndrome. Rev Exp Clin Immunol 2010;6:777-88.

26. Kounis NG. Coronary hypersensitivity disorder: The Kounis syndrome. Clin Ther 2013;35:563-71.

Cite this article as: Kounis NG, Soufras GD, Davlouros P, Tsigkas G, Hahalis G. Combined etiology of anaphylactic cardiogenic shock: Amiodarone, epinephrine, cardioverter defibrillator, left ventricular assist devices and the Kounis syndrome. Ann Card Anaesth 2015:16:261-4.

Source of Support: Nil, Conflict of Interest: None declared.